GenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer

Reuters12-05

GenFleet <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer

GenFleet Therapeutics (Shanghai) Inc. has announced the initiation of a registrational phase III study (GFH375X1301) for GFH375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer. The trial, described as the first-in-world phase III monotherapy study of an oral KRAS G12D inhibitor versus chemotherapy, has commenced at Peking University Cancer Hospital. Results from this study have not yet been presented and will be available in the future. The company has advised shareholders and potential investors to exercise caution, noting that successful development or commercialization of GFH375 cannot be guaranteed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945439), on December 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589385546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589385546","market":"fut","top_or_hot":-1,"title":"GenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GenFleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GenFleet Therapeutics (Shanghai) Inc. has announced the initiation of a registrational phase III study (GFH375X1301) for GFH375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer. The trial, described as the first-in-world phase III monotherapy study of an oral KRAS G12D inhibitor versus chemotherapy, has commenced at Peking University Cancer Hospital. Results from this study have not yet been presented and will be available in the future. The company has advised shareholders and potential investors to exercise caution, noting that successful development or commercialization of GFH375 cannot be guaranteed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945439), on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GenFleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GenFleet Therapeutics (Shanghai) Inc. has announced the initiation of a registrational phase III study (GFH375X1301) for GFH375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer. The trial, described as the first-in-world phase III monotherapy study of an oral KRAS G12D inhibitor versus chemotherapy, has commenced at Peking University Cancer Hospital. Results from this study have not yet been presented and will be available in the future. The company has advised shareholders and potential investors to exercise caution, noting that successful development or commercialization of GFH375 cannot be guaranteed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945439), on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8nlGKK:1","article_id":"2589385546","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589385546","pubTimestamp":1764892870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GenFleet Therapeutics  Inc. has announced the initiation of a registrational phase III study  for GFH375, an oral KRAS G12D  inhibitor, in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer. The trial, described as the first-in-world phase III monotherapy study of an oral KRAS G12D inhibitor versus chemotherapy, has commenced at Peking University Cancer Hospital. Results from this study have not yet been presented and will be available in the future. The company has advised shareholders and potential investors to exercise caution, noting that successful development or commercialization of GFH375 cannot be guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02595":"劲方医药-B"},"translate_title":"GenFleet Therapeutics启动口服KRAS G12D抑制剂治疗转移性胰腺癌III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":0.9},"content_text":"GenFleet Therapeutics Launches Phase III Trial of Oral KRAS G12D Inhibitor for Metastatic Pancreatic Cancer\n    \n\n        GenFleet Therapeutics (Shanghai) Inc. has announced the initiation of a registrational phase III study (GFH375X1301) for GFH375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer. The trial, described as the first-in-world phase III monotherapy study of an oral KRAS G12D inhibitor versus chemotherapy, has commenced at Peking University Cancer Hospital. Results from this study have not yet been presented and will be available in the future. The company has advised shareholders and potential investors to exercise caution, noting that successful development or commercialization of GFH375 cannot be guaranteed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945439), on December 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589385546","isCrawlerRequest":true}